Press releases

Year-end Report 2022

Tue, Feb 28 2023, 7:00 CET | Year-end report | Regulatory release

Increased sales in fourth quarter and full year.

At the beginning of 2022, we were finally able to see the end of the COVID-19 pandemic and have gradually been able to accelerate our activity levels in terms of participation at fairs and congresses and, not least, by being able to have meaningful meetings with our customers. The positive sales trend we have seen during the year continued in the fourth quarter and sales rose by 38 percent to SEK 9.4 (6.8) million. Strengthened by this development, we are now approaching 2023 with great energy and even sharper focus.

October – December 2022

  • Net sales: SEK 9.4 million (6.8), +38%
  • Operating income: SEK -1.8 million (-3.9)
  • Net income for the period: SEK -1.9 million (-4.1)
  • Earnings per share: SEK -0.03 (-0.06)

January – December 2022

  • Net sales: SEK 36.1 million (28.2), +28%
  • Operating income: SEK -8.3 million (-11.8)
  • Net income for the period: SEK -8.6 million (-12.2)
  • Earnings per share: SEK -0.12 (-0.17)

Events during the fourth quarter 2022

  • Glycorex attended national transplant congresses in India, Mexico, South Africa, and Germany.
  • In South Africa, Glycorex sponsored a symposium in blood group incompatible transplants.
  • First order for Glycosorb® ABO from distributor in South Africa.
  • First delivery to Mexico since the COVID-19 pandemic.
  • New transplant centers were added as customers in India and France.
  • Further scientific support for Glycosorb® ABO was presented at the German congress the DTG (der Deutschen Transplantationsgesellschaft).
  • The positive development in India continued during the quarter. Of all organ transplants performed with Glycosorb® ABO during 2022 over 20 percent was liver transplants from living donors.
  • Excellent results were obtained from the platelet evaluation carried out in the UK.

Significant events after the balance sheet date

  • Jan 31, 2023: Glycorex strengthens the organization to place additional force behind the growth strategy Going 4 Growth.
  • Feb 20, 2023: The first blood group incompatible kidney transplant using Glycosorb ® ABO performed in South Africa.

For more information, please contact

Johan Lavén, CEO Glycorex Transplantation AB
Tel: + 46 (0)73 330 92 16

This information is the kind of information Glycorex Transplantation AB (publ) is obliged to make public under the EU Market Abuse Act and the Act on the Securities Market. The information was submitted for publication on February 28, 2023, at 08:00 CET.

Brief information about the company

Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique technology to select and remove specific antibodies in the blood.

Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplants. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific papers have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Each kidney transplant saves about 150 dialysis treatments per year. Glycosorb® ABO has been used on five continents in more than 6,000 transplants. In addition to Europe, Glycosorb® ABO is used in Australia, Canada, India, Israel, Mexico, Singapore, South Africa, and Thailand, for example.

The company has also developed a CE-marked medical device product for the production of universal (low titer) blood products and is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B

Subscribe to our releases

Choose categories

Contact information

The subscription service is provided by and your information will be stored on their servers. The information will only be used to send you notifications when new releases are published. No personal information will be shared with any outside parties. Read more about our Privacy Policy.


Exhibition overview

25 March 2023 – 33. Münsteraner Symposium Nierentransplantation, Germany

24-26 May 2023 – MESOT (Middle East Society For Organ Transplantation), Turkey

1-3 June 2023 – 14th World Congress of the International Society for Apheresis (ISFA), Germany

3-7 June 2023 – ATC (American Transplant Congress), USA

17-21 June 2023 – ISBT (International Society of Blood Transfusion), Sweden

17-20 September 2023 – ESOT (European Society for Organ Transplantation), Greece

26-28 October 2023 – DTG 2023 (Annual Meeting of the German Transplantation Society), Germany


Johan Lavén, CEO presenting Glycorex Transplantation on Aktiedagen (Aktiespararna) September 19 2023.

The presentation on Youtube >>

Geert Nygaard, CEO presenting Glycorex Transplantation on Aktiedagen (Aktiespararna) januari 31 2022.

The presentation on Youtube >>

Pontus Nobréus, CEO presenting Glycorex Transplantation on Redeye Growth Day june 2.
Presentationen >>

Download the presentationen >>


Pontus Nobréus, CEO presenting Glycorex Transplantation  BioStock Life Science Spring Summit on May 26

Download the presentation >>

Glycorex Transplantation is a proud collaborator with The Hospital Clínic de Barcelona in Spain. It recently became the first hospital in Spain to carry out more than 1,000 living donor kidney transplants. To celebrate this milestone, a campaign called “A thousand transplants, a thousand stories” was launched to increase public awareness and encourage living donor kidney donations.

Pontus Nobréus, CEO of Glycorex Transplantation will present at the Redeye Growth Day on June 2, 2021 at 08:50 CET.
Link to live streaming:

Glycorex Transplantation participates in the BioStock Life Science Spring Summit 2021. CEO Pontus Nobréus will present the company at the BioStock Life Science Spring Summit on May 26-27. For more information please visit:

Tomorrow, april 29th, Dr Guirado from Spain will discuss ABO incompatible kidney transplantations in a live Zoom seminar, arranged by our distributor in Mexcio, Ryse Médica and Sociedad Mexicana De Transplantes.

Scheelevägen 27 | SE-223 63 Lund, Sweden

Phone: +46 46 286 52 30  | Fax: +46 46-286 52 39
E-mail: 556519-7372

© 2022 Glycorex Transplantation AB. Registered office in Lund, Sweden . All rights reserved.